# US 2026/0137833 A1 · Biologic Composition And Method Of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0137833 A1
- Document ID: US20260137833A1
- Status: Published application
- Kind: A1
- Application number: 19/442,273
- Filed: 2026-01-07
- Published: 2026-05-21
- Earliest claimed: 2019-12-13
- Assignees: Vivex Biologics Group, Inc.
- Applicants: Vivex Biologics Group, Inc.
- Inventors: Timothy Ganey; Shabnam Namin; Harry Thomas Temple
- Web page: https://patentgrep.com/patent/US20260137833A1

## CPC

- A61L 27/3608: {Bone, e.g. demineralised bone matrix [DBM], bone powder}
- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 27/365: {Bones}
- A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells}
- A61L 27/3847: {Bones}
- A61L 27/3856: {Intervertebral discs (mechanical aspects and structures of intervertebral discs A61F2/442)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61M 5/329: {characterised by features of the needle shaft}
- A61L 2300/214: Amino acids
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/258: Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
- A61L 2300/802: Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/38: for reconstruction of the spine, vertebrae or intervertebral discs
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

A biologic composition responsive to inflammation has an allograft scaffold matrix for injection or implantation. The allograft scaffold matrix has donor quiescent and/or senescent cells. The donor quiescent and/or senescent cells react in response to signaling of inflammation from host cells or matrix. The reaction to signaling causes the donor quiescent and/or senescent cells to secrete anti-inflammatory cytokines and secrete exosomes to initiate regeneration of the area of the inflammation. The biologic composition further has a cryoprotectant. The cryoprotectant is a polyampholyte, preferably the polyampholyte is an ϵ-poly-L-lysine. The cryoprotectant is not DMSO or glycerol based. The cryoprotectant is suitable for direct implantation without washing from the allograft scaffold matrix in either a diluted or non-diluted state.

## Claims

### Claim 1

A method of treating and repairing a degenerative condition comprising
implanting a viable allograft comprising donor quiescent and/or senescent cells into a degenerated area exhibiting inflammation,
wherein the implanting causes the donor quiescent and/or senescent cells to receive signaling from host cells indicating inflammation, and
wherein the signaling activates the donor quiescent and/or senescent cells and causes the donor quiescent and/or senescent cells to secrete anti-inflammatory cytokines and exosomes directed to the host cells, thereby reducing the inflammation and initiating regeneration of the degenerated area.

### Claim 2 (depends on 1)

The method of claim 1 wherein the activation of the donor quiescent and/or senescent cells in response to the signaling causes secretion and exchange of microvesicles, membrane rafts, miRNA, proteins, growth factors, and/or cytokines, and ions appropriate for tissue function.

### Claim 3 (depends on 1)

The method of claim 1, wherein the degenerated area is a bone, cartilage, neurological tissue, or ischemic heart tissue.

### Claim 4 (depends on 1)

The method of claim 1, wherein the donor quiescent and senescent cells are derived from bone marrow.

### Claim 5 (depends on 1)

The method of claim 1, wherein the donor senescent cells are derived from placental tissue.

### Claim 6 (depends on 1)

The method of claim 1, wherein the allograft further comprises an allograft scaffold matrix in the form of chips, fibers, or particles or combinations thereof, wherein the allograft scaffold matrix is made of bone, cartilage, nucleus pulposus, or dermis material, and wherein the donor quiescent and senescent cells are seeded onto or loaded into the allograft scaffold matrix.

### Claim 7 (depends on 1)

The method of claim 1, wherein the allograft scaffold matrix in the form of allograft chips, fibers, or particles or combinations thereof comprises mineralized, demineralized, partially demineralized, or combinations of mineralized and demineralized bone chips, bone fibers or bone particles or any combination thereof.

### Claim 8 (depends on 6)

The method of claim 6, wherein the allograft scaffold matrix further comprises nucleus pulposus particles or fibers or combinations thereof.

### Claim 9 (depends on 6)

The method of claim 6, wherein the allograft scaffold matrix further comprises proteins.

### Claim 10 (depends on 1)

The method of claim 1, wherein the donor quiescent and/or senescent cells are pre-treated with a cryoprotectant.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cryoprotectant is a polyampholyte.

### Claim 12

A method of treating a degenerative intervertebral disc comprising
implanting a viable allograft scaffold matrix having donor quiescent and/or senescent cells into a degenerative intervertebral disc exhibiting inflammation,
wherein the implanting causes the donor quiescent and/or senescent cells to receive signaling from host cells indicating inflammation, and
wherein the signaling activates the donor quiescent and/or senescent cells and causes the donor quiescent and/or senescent cells to secrete anti-inflammatory cytokines and exosomes directed to the host cells,
thereby reducing the inflammation and initiating regeneration of the nucleus polposus of the degenerative intervertebral disc.

### Claim 13 (depends on 12)

The method of claim 12, wherein the height of the treated degenerative intervertebral disc is increased relative to an untreated degenerative intervertebral disc.

### Claim 14 (depends on 12)

The method of claim 12, wherein the activation of the donor quiescent and/or senescent cells in response to the signaling causes secretion and exchange of microvesicles, membrane rafts, miRNA, proteins, growth factors, and/or cytokines, and ions appropriate for tissue function.

### Claim 15 (depends on 12)

The method of claim 12, wherein the donor quiescent and senescent cells are derived from bone marrow.

### Claim 16 (depends on 12)

The method of claim 12, wherein the donor senescent cells are derived from placental tissue.

### Claim 17 (depends on 12)

The method of claim 12, wherein the allograft further comprises an allograft scaffold matrix in the form of chips, fibers, or particles or combinations thereof, wherein the allograft scaffold matrix is made of bone, cartilage, nucleus pulposus, or dermis material, and wherein the donor quiescent and senescent cells are seeded onto or loaded into the allograft scaffold matrix.

### Claim 18 (depends on 17)

The method of claim 17, wherein the allograft scaffold matrix in the form of allograft chips, fibers, or particles or combinations thereof comprises mineralized, demineralized, partially demineralized, or combinations of mineralized and demineralized bone chips, bone fibers or bone particles or any combination thereof.

### Claim 19 (depends on 17)

The method of claim 17, wherein the allograft scaffold matrix further comprises nucleus pulposus particles or fibers or combinations thereof.

### Claim 20 (depends on 17)

The method of claim 17, wherein the allograft scaffold matrix further comprises proteins.

### Claim 21 (depends on 12)

The method of claim 12, wherein the donor quiescent and/or senescent cells are pre-treated with a cryoprotectant.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cryoprotectant is a polyampholyte.
